Unity Biotechnology (NASDAQ:UBX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Unity Biotechnology (NASDAQ:UBX) posted its quarterly earnings results on Monday. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02, Zacks reports.

Unity Biotechnology Stock Performance

Shares of UBX opened at $1.21 on Wednesday. The stock has a market capitalization of $20.39 million, a price-to-earnings ratio of -0.92 and a beta of 0.83. Unity Biotechnology has a 52-week low of $1.12 and a 52-week high of $2.26. The stock’s 50-day simple moving average is $1.44 and its 200 day simple moving average is $1.47.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on UBX. Rodman & Renshaw initiated coverage on Unity Biotechnology in a research note on Thursday, August 22nd. They set a “buy” rating and a $8.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Unity Biotechnology in a research report on Thursday, August 8th.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.